Clinical Worsening After Bamlanivimab Administration Clinical worsening after administration of bamlanivimab has been reported and may include signs or symptoms of fever, hypoxia or increased ...

CHMP scientific opinion supports national decision-making within European Union (EU) member states on the use of the antibodies during a public health emergency before a formal marketing authorization ...

The ASPR will resume distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supply of bamlanivimab at a facility) to certain states. The Food and Drug ...

INDIANAPOLIS, April 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies ...

INDIANAPOLIS , March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating ...

Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19. INDIANAPOLIS, Feb. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug ...

The EUA was authorized based on data from the ongoing randomized, double-blind, placebo-controlled phase 2 BLAZE-1 study. The Food and Drug Administration (FDA) has issued an Emergency Use ...

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults ...

Eli Lilly said on Friday it had requested the U.S. health regulator to revoke the emergency use authorization granted to its Covid-19 antibody, bamlanivimab. The request made to the U.S. Food and Drug ...

Bamlanivimab and VIR-7831 bind to different regions of the spike protein of SARS-CoV-2. Preclinical data suggest the administration of these two investigational antibodies together may provide ...